The 14.92% discount and ~4.3% dilution create near-term selling pressure. Watch for the over-allotment option exercise (up to 15% more ADSs) which would increase dilution. The cash runway into 2029 is a positive, but the offering signals capital needs beyond current burn. Monitor trading volume and price action on Nasdaq today after the Euronext suspension lifts.
Price Chart
Executive Summary
Nanobiotix priced a global follow-on offering raising ~$98.6M gross ($85M equivalent) via 2,184,662 ordinary shares (including ADSs) and 345,099 pre-funded warrants at $38.98/ADS (€33.60/share), a 14.92% discount to the VWAP. The offering dilutes non-participating shareholders by ~4.3% on a non-diluted basis, but extends cash runway into 2029 and was supported by existing large holders Invus and Qatar Holding. The dilutive discount and share overhang are bearish near-term, though the cash infusion removes financing risk.
Key Financial Metrics
Key Facts
- Gross proceeds of ~$98.6M (~€85M) from 2,184,662 ordinary shares (including ADSs) and 345,099 pre-funded warrants.
- Offering priced at $38.98/ADS (€33.60/share), a 14.92% discount to the 3-day VWAP on Euronext.
- Existing shareholders Invus and Qatar Holding participated, indicating insider support.
- Dilution of ~4.3% for non-participating shareholders on a non-diluted basis (from 1.0000% to 0.9568% ownership).
- Cash runway extended into 2029; net proceeds allocated <10% to JNJ-1900 (NBTXR3), 50-60% to Nanoprimer and other platforms, 30-40% for general corporate purposes.
- 90-day lock-up for executive board, supervisory board, and the company.
- Underwriters have a 30-day option to purchase up to 15% additional ADSs (over-allotment).
- Equity per share was -€1.75 before the offering and improves to -€1.67 after (non-diluted), reflecting the cash injection.
Financial Impact
~$98.6M gross proceeds raised at a 14.92% discount to market, diluting existing holders by ~4.3%.
Risk Factors
- Near-term price decline due to dilutive discount and share overhang.
- Over-allotment option could add up to 15% more ADSs, increasing dilution.
- Pre-funded warrants (345,099 shares) exercisable until 2036 add future dilution if exercised.
- Use of proceeds heavily weighted toward early-stage platforms (50-60% for Nanoprimer) with uncertain clinical outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299513 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+20 | — | — |
Oct 20, 2026 6d ago | 6-K | $25.83 | awaiting T+20 | — | $31.53 (+22.07%) |
Oct 1, 2026 25d ago | 6-K | $25.75 | awaiting T+20 | — | $31.53 (+22.45%) |
Oct 1, 2026 25d ago | Press Release | $25.75 | awaiting T+20 | — | $31.53 (+22.45%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▲ +11.86% | ▲ +10.38% | $31.53 (+5.34%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.53 (−5.34%) |
Sep 24, 2026 4w ago | Press Release | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.53 (−5.34%) |
Sep 22, 2026 4w ago | Press Release | $35.24 $25.83 | ▼ −26.70% | ▼ −27.39% | $31.53 (−10.53%) |
Sep 14, 2026 6w ago | 6-K | $35.73 $23.40 | ▼ −34.51% | ▼ −36.77% | $31.53 (−11.75%) |
Jul 31, 2026 12w ago | 6-K | $38.89 $40.64 | ▲ +4.50% | ▲ +3.26% | $31.53 (−18.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers